Enlivex Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -160 | -188 | -200 | -200 |
EBITDA | -2,826 | -3,762 | -5,891 | -5,891 |
EBIT | -2,986 | -3,950 | -5,934 | -6,091 |
Net Income | -3,096 | -4,140 | -9,095 | -9,095 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -1,813 | -4,552 | -5,032 | -5,032 |
Cash | 3,747 | 2,025 | 926 | 926 |
Basic Shares | 19,545 | 18,727 | 18,598 | 18,598 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $2,277 |
Gross Profit | -835 | -777 | -546 | 1,991 |
EBITDA | -28,219 | -25,020 | -18,742 | -9,499 |
EBIT | -29,054 | -25,797 | -19,288 | -9,785 |
Net Income | -29,068 | -42,407 | -9,648 | -13,863 |
Net Change In Cash | 0 | 0 | 0 | 2,277 |
Free Cash Flow | -23,759 | -32,075 | -19,167 | -12,026 |
Cash | 926 | 47,822 | 11,202 | 5,673 |
Basic Shares | 18,574 | 18,394 | 17,859 | 13,169 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.16 |
2024-03-31 | -$0.22 |
2023-12-31 | -$0.48 |
2023-09-30 | -$0.32 |
